Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Alfred H. Schinkel(Oncode Institute), Glen Reid(University of Otago), Martin van der Valk, Arnold van Loevezijn, Olaf van Tellingen(Dutch Cancer Society), Jeany M Lakhai, Jan H.M. Schellens(Utrecht University), Gerrit‐Jan Koomen
PubMed
April 1, 2002
Cited by 688
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884